After the EU’s vaccine distribution disaster, German lawmakers are now taking a closer look at Russia’s Sputnik V jab. If approved by EU regulators, Sputnik V could be the fourth vaccine available in the bloc after the BioNTech-Pfizer, Moderna and AstraZeneca vaccines.
It’s easy to see why Germany could be tempted by the Sputnik V vaccine. The rollout of the BioNTech-Pfizer and Moderna jabs has been hampered by delivery delays and political blunders. And European regulators have remained wary of AstraZeneca’s vaccine – a scepticism that was solidified by a recent trial showing that the shot may not significantly reduce the risk of mild or moderate disease caused by the 501Y.V2 variant, also known as the South African strain.
Meanwhile, the Lancet reported last week that Sputnik V, which was developed at Russia’s Gamaleya National Research Center for Epidemiology and Microbiology, was 91.6
Comments
Join the debate for just $5 for 3 months
Be part of the conversation with other Spectator readers by getting your first three months for $5.
UNLOCK ACCESS Just $5 for 3 monthsAlready a subscriber? Log in